Etifoxine Explained

Etifoxine, sold under the trade name Stresam among others, is a nonbenzodiazepine anxiolytic agent, primarily indicated for short-term management of adjustment disorder, specifically instances of situational depression accompanied by anxiety, such as stress-induced anxiety.[1] [2] Administration is by mouth.[3] Side effects associated with etifoxine use include slight drowsiness, headache, skin eruptions, and allergic reactions.[4] In rare cases, etifoxine has been linked to severe skin and liver toxicity, as well as menstrual bleeding between periods. Unlike benzodiazepines, etifoxine does not cause sedation or lack of coordination.[5] [6] Etifoxine acts as a GABAA receptor positive allosteric modulator and as a ligand for translocator proteins. Both mechanisms are conjectured to contribute to its anxiolytic properties.

Etifoxine was developed in the 1960s and was introduced for medical use in France in 1979. Its marketed in 53 countries worldwide, although it remains unavailable in the United States.[7] Throughout the 2010s and early 2020s, the safety profile of etifoxine was scrutinized within France and the European Union, prompted by reports of toxicity. The investigation revealed that instances of toxicity were infrequent, and etifoxine was allowed to remain on the market.

Medical uses

Etifoxine has historically been used in the treatment of "psychosomatic manifestations of anxiety", for instance "autonomic dystonia, particularly with cardiovascular expression". Subsequently, the indication for etifoxine has been more formalized as treatment of adjustment disorder (situational depression) with anxiety (ADWA) (e.g., stress-related anxiety).[8] Etifoxine has been found to reduce scores on the Hamilton Anxiety Rating Scale (HAM-A) in people with adjustment disorder with anxiety by approximately 50 to 75% after 4weeks of treatment in clinical trials (e.g., AMETIS, ETILOR, ETIZAL, STRETI studies). The medication is similarly effective or more effective than benzodiazepines like lorazepam, alprazolam, and clonazepam and more effective than buspirone for adjustment disorder with anxiety on the basis of directly comparative randomized controlled trials.[9] [10] [11] [12] However, in the AMETIS study, both etifoxine and lorazepam failed to show greater effectiveness over placebo.

The usual dosage of etifoxine (as the hydrochloride salt) is 150 to 200mg per day in divided doses of 50 to 100mg two to three times per day (e.g., 50mg–50mg–100mg).[13] [14] [15] It is taken for a few days to a few weeks, but no longer than 12weeks.

Available forms

Etifoxine is provided in the form of oral capsules containing 50mg etifoxine hydrochloride.[16] [17]

Contraindications

Etifoxine is contraindicated in people with circulatory shock, severe liver impairment, severe kidney impairment, myasthenia gravis, galactosemia (due to lactose in the drug formulation), severe respiratory failure, and hypersensitivity (allergy) to etifoxine.[18] The medication is not recommended in children or adolescents under the age of 18 and is not recommended during pregnancy and breastfeeding due to insufficient data. Caution is warranted with regard to combining etifoxine and other central depressants such as benzodiazepines, central analgesics, antipsychotics, sedative antihistamines, and alcohol.

Side effects

Side effects of etifoxine include slight drowsiness and headache. Rarely, etifoxine can cause benign skin eruptions or rashes and allergic reactions such as hives and angioedema. Etifoxine shows less adverse effects of anterograde amnesia, sedation, impaired psychomotor performance, and withdrawal syndromes than those of benzodiazepines.[18] No cases of misuse or dependence with etifoxine were identified in a French pharmacovigilance survey, which is also in contrast to benzodiazepines.

Etifoxine has been associated rarely with cases of severe dermal toxicity and liver toxicity.[19] [20] Skin and subcutaneous disorders are the most frequently reported, but these generally resolve after drug cessation. A 2012 review of etifoxine by the French National Pharmacovigilance Committee determined that etifoxine was safe and continued to provide a favorable alternative to benzodiazepine anxiolytics. The committee found (for a ten-year pharmacovigilance period) that safety concerns were rare or very rare and that the incidence of idiosyncratic hepatic (liver) problems were very rare.[21]

Pharmacology

Pharmacodynamics

Unlike benzodiazepines, etifoxine may produce its anxiolytic effects through a dual mechanism, by directly binding to GABAA receptors and (purportedly, exact binding site undetermined) to the mitochondrial translocator protein (TSPO). This results in stimulation of the biosynthesis of endogenous neurosteroids, for instance allopregnanolone, a highly potent GABAA receptor positive allosteric modulator.

At GABAA receptors etifoxine binds at the α+β− interface and preferentially potentiates α2β3γ2 and α3β3γ2 receptor types.[22] This direct allosteric potentiation can only be observed at relatively high concentrations (starting at >1mM) and is perhaps not physiologically relevant at normal human doses.[23] This is different from benzodiazepines and etifoxine can be used alongside benzodiazepines to potentiate their effects without competing for binding sites;[24] however, it also means that the direct effects of etifoxine are not reversed by the benzodiazepine antagonist flumazenil.[25]

Pharmacokinetics

Etifoxine is taken via oral administration. It is rapidly absorbed from the gastrointestinal tract. It is well-absorbed, with a bioavailability of 90%. The time to peak levels of etifoxine is 2 to 3hours. The plasma protein binding of etifoxine is 88 to 95%. It does not bind to blood cells. The drug is known to cross the placental barrier. Etifoxine is metabolized in the liver into several metabolites. One of these metabolites, diethyletifoxine, is pharmacologically active. The elimination half-life of etifoxine is 6hours and of diethyletifoxine is almost 20hours. Etifoxine is eliminated in three phases. The drug is excreted mainly in urine in the form of metabolites. It is also excreted in bile. Only small amounts are excreted unchanged.

Chemistry

Etifoxine is a nonbenzodiazepine—that is, it is similarly a GABAA receptor positive allosteric modulator but its chemical structure is distinct from that of benzodiazepines.[26] Instead, it is a benzoxazine derivative.

Etifoxine is used pharmaceutically as the hydrochloride salt.

(S)-Etifoxine, the (S) enantiomer of etifoxine, was under development by Anvyl Pharmaceuticals for the treatment of neuropathic pain, but development was discontinued.[27] A deuterated form of etifoxine with improved pharmacokinetics known as deuterated etifoxine (GRX-917) is under development by GABA Therapeutics for the treatment anxiety and mood disorders.[28] [29] [30] [31]

History

Etifoxine was developed by Hoechst in the 1960s. It was introduced for medical use in France in 1979. Since at least 2000, etifoxine has been marketed by the French pharmaceutical company Biocodex.[32] Following reports of post-marketing toxicity, the safety of etifoxine was reassessed by the French government and the European Medicines Agency (EMA). In January 2022, the EMA "finalized its review of Stresam and concluded that the medicine can continue to be used for the treatment of anxiety disorders, but it must not be used in patients who previously had severe skin reactions or severe liver problems after taking etifoxine."[33] [34]

Society and culture

Names

Etifoxine is the generic name of the drug and its,, and .[35] [36] It is also known by the older and much-lesser-used synonym etafenoxine[37] and by its developmental code name Hoe 36801. Etifoxine is marketed under the brand name Stresam. It has also been marketed under the brand name Strezam, specifically in Russia.

Availability

Etifoxine has been marketed in 53countries as of 2022.[38] Some of the countries in which etifoxine has been marketed include Argentina, Bulgaria, Chile, France, Luxembourg, Malta, Romania, Russia, South Africa, Thailand, and Ukraine.[39] Etifoxine is not approved for use by the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) of the European Union, and hence is not marketed in these regions. However, etifoxine is marketed in five European Union member states (France, Bulgaria, Luxembourg, Malta, Romania).

See also

Further reading

External links

Notes and References

  1. Web site: July 2010 . STRESAM®, capsule Summary of Product Characteristics . https://web.archive.org/web/20211024130823/https://gabarx.com/wp-content/uploads/2018/05/StresamSPC-1.pdf . 24 October 2021 . GABA Therapeutics, Inc.
  2. Besnier N, Blin O . January 2008 . Étifoxine : études cliniques récentes . Etifoxine: recent clinical studies . L'Encéphale . fr . 34 . Suppl 1 (Etifoxine : un nouveau regard sur le récepteur GABA et l'anxiété) . S9–S14 . 10.1016/S0013-7006(08)71386-1 . 0013-7006.
  3. Web site: 27 January 2022 . INN/active substance: etifoxine Assessment report . https://web.archive.org/web/20230207211200/https://gabarx.com/wp-content/uploads/2022/06/etifoxine-containing-medicinal-products-article-31-referral-public-assessment-report-including_en.pdf . 7 February 2023 . European Medicines Agency.
  4. Deplanque D, Machuron F, Waucquier N, Jozefowicz E, Duhem S, Somers S, Colin O, Duhamel A, Bordet R . August 2018 . Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study . Eur Neuropsychopharmacol . 28 . 8 . 925–932 . 10.1016/j.euroneuro.2018.05.011 . 30135030 . 52066957.
  5. Poisbeau P, Gazzo G, Calvel L . 2018 . Anxiolytics targeting GABAA receptors: Insights on etifoxine . World J Biol Psychiatry . 19 . sup1 . S36–S45 . 10.1080/15622975.2018.1468030 . 30204559 . 52191153 . free.
  6. Nuss P, Ferreri F, Bourin M . 2019 . An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action . Neuropsychiatr Dis Treat . 15 . 1781–1795 . 10.2147/NDT.S200568 . 6615018 . 31308671 . free.
  7. Web site: 2019-10-07 . Hermitage Man Sentenced for Importing and Selling Drugs Not Approved by FDA . 2022-05-12 . www.justice.gov . en.
  8. Stein DJ . 2018 . Pharmacotherapy of adjustment disorder: A review . World J Biol Psychiatry . 19 . sup1 . S46–S52 . 10.1080/15622975.2018.1492736 . 30204560 . 52187107 . free.
  9. Servant D, Graziani PL, Moyse D, Parquet PJ . 1998 . Traitement du trouble de l'adaptation avec anxiété: évaluation de l'efficacité et de la tolérance de l'étifoxine par un essai en double aveugle contre produit de référence . Treatment of adjustment disorder with anxiety: efficacy and tolerance of etifoxine in a double-blind controlled study . Encephale . French . 24 . 6 . 569–74 . 9949940.
  10. Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O . April 2006 . Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice . Hum Psychopharmacol . 21 . 3 . 139–49 . 10.1002/hup.757 . 16625522 . 25940120.
  11. Stein DJ . January 2015 . Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial . Adv Ther . 32 . 1 . 57–68 . 10.1007/s12325-015-0176-6 . 4311065 . 25620535.
  12. Vicente B, Saldivia S, Hormazabal N, Bustos C, Rubí P . November 2020 . Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial . Psychopharmacology (Berl) . 237 . 11 . 3357–3367 . 10.1007/s00213-020-05617-6 . 33009629 . 222165607.
  13. Spadone C, Glikman M . April 2008 . L'étifoxine: un nouveau regard sur le récepteur GABA et l'anxiété . Etifoxine: a new look at the GABA receptor and anxiety . Encephale . French . 34 Spec No 1 . 1–11 . 10.1016/S0013-7006(08)70553-0 . 0013-7006 . 18826172.
  14. Book: Afect . Traité de chimie thérapeutique Volume 7: Médicaments actifs sur le système nerveux central . 1 May 2011 . Lavoisier . 978-2-7430-1373-8 . 500– . 758328876 . 5.2. Propriétés pharmacologiques. [...] 5.2.2. Étifoxine. Utilisé dans les manifestations psychosomatiques de l'anxiété, telles que les dystonies neurovégétatives (Stresam, gélules à 50 mg). La posologie usuelle est de 150 à 200 mg/j. 5.4. Effets indésirables. [...] 5.4.2. Étifoxine. Légère somnolence en début de traitement, éruptions cutanées rares. 5.5. Contre-indications et précautions d'emploi. [...] 5.5.2. Étifoxine. Précaution lors d'association avec les dépresseurs centraux (benzodiazepines, analgesiques centraux, neuroleptiques, antihistaminiques H1 sédatifs, etc.). L'alcool potentialise l'effet sédatif de l'étifoxine. Ce produit est déconseillé pendant la grossesse et en cas d'allaitement..
  15. Micallef J, Soubrouillard C, Guet F, Le Guern ME, Alquier C, Bruguerolle B, Blin O . June 2001 . A double blind parallel group placebo controlled comparison of sedative and mnesic effects of etifoxine and lorazepam in healthy subjects [corrected] . Fundam Clin Pharmacol . 15 . 3 . 209–16 . 10.1046/j.1472-8206.2001.00025.x . 11468032 . 73049654.
  16. Book: Concours Médical, Volume 123, Issues 34-40 . 2001 . 2361 . 1564649 . STRESAM gélule . COMPOSITION - Etifoxine chlorhydrate, 50 mg par gélule . Excipients q.s.p. 1 géluie de 200 mg . INDICATIONS THÉRAPEUTIQUES - Manifestations psychosomatiques de l'anxiété telles que dystonies neurovégétatives [...].
  17. Book: Le préparateur en pharmacie - Guide théorique et pratique (2e ed.) . Gazengel JM, Orecchioni AM . 15 April 2013 . Lavoisier . 978-2-7430-6371-9 . 820– . 1005722892 . L'étifoxine (Stresam®, gél 50 mg, liste I) a son indication dans les manifestations psychosomatiques de l'anxiété telles que dystonies neurovégétatives, notamment à expression cardiovasculaire..
  18. Choi YM, Kim KH . January 2015 . Etifoxine for pain patients with anxiety . Korean J Pain . 28 . 1 . 4–10 . 10.3344/kjp.2015.28.1.4 . 4293506 . 25589941.
  19. Cottin J, Gouraud A, Jean-Pastor MJ, Dautriche AD, Boulay C, Geniaux H, Auffret M, Bernard N, Descotes J, Vial T . April 2016 . Safety profile of etifoxine: A French pharmacovigilance survey . Fundam Clin Pharmacol . 30 . 2 . 147–52 . 10.1111/fcp.12169 . 26588183 . 7599622.
  20. Moch C, Rocher F, Lainé P, Lacotte J, Biour M, Gouraud A, Bernard N, Descotes J, Vial T . October 2012 . Etifoxine-induced acute hepatitis: a case series . Clin Res Hepatol Gastroenterol . 36 . 5 . e85–8 . 10.1016/j.clinre.2012.04.002 . 22633197.
  21. Web site: COMMISSION NATIONALE DE PHARMACOVIGILANCE Compte rendu de la réunion du mardi 26 juin 2012 . https://web.archive.org/web/20210309092902/http://ansm.sante.fr/var/ansm_site/storage/original/application/56a2e1cb1dbc986720da09842df11c22.pdf . 2021-03-09 . fr.
  22. Mattei C, Taly A, Soualah Z, Saulais O, Henrion D, Guérineau NC, Verleye M, Legros C . 2019 . Involvement of the GABAA receptor α subunit in the mode of action of etifoxine . Pharmacol. Res. . 145 . 104250 . 10.1016/j.phrs.2019.04.034 . 31059790 . free.
  23. Hamon A, Morel A, Hue B, Verleye M, Gillardin JM . 2003 . The modulatory effects of etifoxine's direct effects on GABA(A) receptors are mediated by the beta subunit . Neuropharmacology . 45 . 3 . 293–303 . 10.1016/s0028-3908(03)00187-4 . 12871647 . 9892214.
  24. Kruse HJ, Kuch H . 1986 . Potentiation of clobazam's anticonvulsant activity by etifoxine, a non-benzodiazepine tranquilizer, in mice. Comparison studies with sodium valproate . Arzneimittelforschung . 36 . 9 . 1320–2 . 3098254.
  25. Verleye M, Schlichter R, Gillardin JM . 1999 . Interactions of etifoxine with the chloride channel coupled to the GABA(A) receptor complex . NeuroReport . 10 . 15 . 3207–10 . 10.1097/00001756-199910190-00015 . 10574561.
  26. Girard C, Liu S, Adams D, Lacroix C, Sinéus M, Boucher C, Papadopoulos V, Rupprecht R, Schumacher M, Groyer G . January 2012 . Axonal regeneration and neuroinflammation: roles for the translocator protein 18 kDa . J Neuroendocrinol . 24 . 1 . 71–81 . 10.1111/j.1365-2826.2011.02215.x . 21951109 . 21312172.
  27. Web site: S-Etifoxine - AdisInsight .
  28. Web site: Etifoxine deuterated - GABA Therapeutics - AdisInsight .
  29. Rupprecht R, Wetzel CH, Dorostkar M, Herms J, Albert NL, Schwarzbach J, Schumacher M, Neumann ID . July 2022 . Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders? . Mol Psychiatry . 27 . 7 . 2918–2926 . 10.1038/s41380-022-01561-3 . 35444254 . 248245591.
  30. Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G . December 2022 . Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options . Eur Arch Psychiatry Clin Neurosci . 273 . 7 . 1477–1487 . 10.1007/s00406-022-01532-3 . 36574032 . 255205221.
  31. Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A, Kivell BM, Knutson DE, Sharmin D, Pandey KP, Mian MY, Cook JM, Cerne R . February 2022 . The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders . Pharmacol Biochem Behav . 213 . 173321 . 10.1016/j.pbb.2021.173321 . 35041859 . 245963990.
  32. Barresi E, Robello M, Costa B, Da Pozzo E, Baglini E, Salerno S, Da Settimo F, Martini C, Taliani S . January 2021 . An update into the medicinal chemistry of translocator protein (TSPO) ligands . Eur J Med Chem . 209 . 112924 . 10.1016/j.ejmech.2020.112924 . 33081988 . 224823944.
  33. Web site: 27 January 2022 . Etifoxine-containing medicinal products . May 12, 2022 . European Medicines Agency.
  34. Web site: January 31, 2022 . EU OKs Continued Use Of Etifoxine For Anxiety Despite Toxicity Concerns . May 12, 2022 . Pink Sheet Informa Pharma Intelligence.
  35. Book: The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . 14 November 2014 . Springer . 978-1-4757-2085-3 . Elks J . 523– . 1058412474.
  36. Book: Swiss Pharmaceutical Society . Index Nominum 2000: International Drug Directory . 2000 . Taylor & Francis . 978-3-88763-075-1 . 416–.
  37. Kim T, Pae AN . November 2016 . Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2) . Expert Opin Ther Pat . 26 . 11 . 1353–1366 . 10.1080/13543776.2016.1230605 . 27599163 . 21582859.
  38. Sartori SB, Singewald N . December 2019 . Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders . Pharmacol Ther . 204 . 107402 . 10.1016/j.pharmthera.2019.107402 . 31470029 . 201785150 . free.
  39. Web site: Micromedex Products: Please Login .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Etifoxine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.